L3VLUP
ProSign in

AXGN in the 13F filings

Axogen Inc · CUSIP 05463X106

Sector · Medical devices and instrumentsTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Surgical, medical and electromedical devices
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q4 2022Q3 2022Q2 2022Q1 2022Q4 2021Q3 2021Q2 2021
Quarter end
31 Dec 2022
the date the book describes
Filed
15 May 2023
up to 45 days after the quarter end
Managers listing it
1
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q3 2022 and Q4 2022; 1 listed it in both
Shares listed
1,815,000
combined, among listed positions
Reported value
$18m
combined, at the quarter end

Managers listing AXGN in Q4 2022

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q3 2022, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

1 of 1 holder

ActionFiling
Point72 Asset Management LP1,815,000$18m0.06%Trimmed-349,72215 May 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q3 2022 to Q4 2022, among managers that listed it in both quarters or opened it.

Increases

No increase among listed positions.

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (0)

No new position among listed positions.

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q2 2022 to 2 in Q2 2026

Tracked managers listing it, at least.

0246split2017201820192020202120222026
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
AXGN by quarter
QuarterHoldersReported valueBuyersSellers
Q4 20161$1.1mn.a.n.a.
Q1 20171$1.3mn.a.n.a.
Q2 20171$2.0mn.a.n.a.
Q3 20171$2.3mn.a.n.a.
Q4 20172$4.8mn.a.n.a.
Q1 20182$7.1mn.a.n.a.
Q2 2018 (split)5$126mn.a.n.a.
Q3 20184$42mn.a.n.a.
Q4 20184$44mn.a.n.a.
Q1 20194$37mn.a.n.a.
Q2 20194$32mn.a.n.a.
Q3 20191$12mn.a.n.a.
Q4 20191$18mn.a.n.a.
Q1 20202$11mn.a.n.a.
Q2 20201$10.0mn.a.n.a.
Q3 20201$13mn.a.n.a.
Q4 20201$21mn.a.n.a.
Q1 20212$36mn.a.n.a.
Q2 20212$52mn.a.n.a.
Q3 20212$36mn.a.n.a.
Q4 20211$2.4mn.a.n.a.
Q1 20221$4kn.a.n.a.
Q2 20222$17mn.a.n.a.
Q3 20221$26mn.a.n.a.
Q4 20221$18mn.a.n.a.
Q2 20251$1.9m10
Q3 20251$7.7m10
Q4 20251$13m118
Q1 20263$66m149
Q2 20262$41m157

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

AXGN and LLY →AXGN and JNJ →AXGN and VRTX →Choose a stock to compare with AXGN →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own AXGN, latest filings →Back to the 13F Explorer →